Immunetics, Inc., have launched its new MycoDx™ assay for invasive fungal infections, which will be offered through its clinical reference laboratory service in the US.

MycoDx™ is a multiplex molecular assay developed by Immunetics that can identify 21 fungal pathogens in a whole blood sample. Clinical samples can be tested directly with MycoDx, eliminating the prior culturing step required by many other assays. This capability reduces assay turnaround time, providing earlier results to clinicians to enable more effective treatment of life-threatening fungal infections.

The MycoDx Assay available through Immunetics’ clinical reference laboratory will provide:

• Results for a panel of 21 fungal targets including Candida, Aspergillus, Cryptococcus, Coccidioides, Fusarium and other species. Additional fungal targets are currently under development.
• Results directly from whole blood patient samples – no blood cultures required. Additional sample types are currently under development.
• Rapid assay turnaround time - 8 hours for all 21 targets (most current methods can take 48-72 hours or more)